In the BioHarmony Drug Report Database
Erenumab
Aimovig (erenumab) is an antibody pharmaceutical. Erenumab was first approved as Aimovig on 2018-05-17. It has been approved in Europe to treat migraine disorders. It is known to target calcitonin gene-related peptide type 1 receptor.
Trade Name
|
Aimovig |
|---|---|
Common Name
|
erenumab |
ChEMBL ID
|
CHEMBL3833329 |
Indication
|
migraine disorders |
Drug Class
|
Monoclonal antibodies: fully human, neural indications |
Image (chem structure or protein)
